Reference

1. Thorn CF, Klein TE, Altman RB (2010) Pharmacogenomics and bioinformatics: pharm GKB. Pharmacogenomics 11:501–505
2. Mancinelli L, Cronin M, Sadée W. Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci. 2000;2(1):E4-E.
3. Roses, A. D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev. Genet. 5, 645–656 (2004).
4. Roses, A. D. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev. Genet.
5. 645–656 (2004). 5. Haga, S. B., & Burke, W. Using pharmacogenetics to improve drug safety and efficacy. Journal of the American Medical Association 291, 2869–2871 (2004)
6. Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. AAPS J. 20, 4 (2018).
7. Ji, Y., Si, Y., McMillin, G.A. & Lyon, E. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. Expert Rev. Mol. Diagn. 18, 411–421 (2018).
8. Weinshilboum, R., & Wang, L. Pharmacogenomics: Bench to bedside. Nature Reviews Drug Discovery 3, 739–748 (2004) doi:10.1038/nrd1497
9. Roses, A. D. Pharmacogenetics and the practice of medicine. Nature 405, 857–865 (2000).
10. Patel JN. Application of genotype-guided cancer therapy in solid tumors. Pharmacogenomics.
11. . Harris LN, Ismaila N, McShane LM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34
12. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5- fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147) J Natl Cancer Inst. 2014;106
13. Ji, Y., Si, Y., McMillin, G.A. & Lyon, E. Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. Expert Rev. Mol. Diagn. 18, 411–421 (2018
14. Lauschke, V.M., Milani, L. & Ingelman-Sundberg, M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. AAPS J. 20, 4 (2018).
15. .Int J Biomed Investig. Author manuscript; available in PMC 2020 May 28.Published in final edited form as:Int J Biomed Investig. 2018; 1(2): 111. Published online 2018 .
16. Wang L, McLeod H, Weinshilboum RM. Genomics and drug response. N Engl J Med. 2011
17. Food and drug administration. Table of Pharmacogenomics Biomarkers in Drug Labelling with Labelling Text
18. Sorich M, Coory M. Interpreting the clinical utility of a pharmacogenomics marker based obarvational association studies. Pharmacogenomics
19. Fertil Steril. Author manuscript; available in PMC 2019 Jun 1.Published in final edited form as:Fertil Steril. 2018.
20. Ventola CL. Pharmacogenomics in clinical practice: reality and expectations. P T.2016
21. Int J Biomed Investig. Author manuscript; available in PMC 2020 May 28.Published in final edited form as:Int J Biomed Investig. 2018; 1(2): 111. Published online 2018 May 27
22. Cost effectiveness analyses of pharmacological treatments in heart failure Audrey Huili Lim,Nusaibah Abdul Rahim,Jinxin Zhao,S. Y. Amy Cheung and Yu-Wei Lin
23. Clin Pharmacol Ther. Author manuscript; available in PMC 2013 Apr 1.Published in final edited form as:Clin
24. J Clin Med Res. 2009 Oct; 1(4): 191–194. Published online 2009 Oct 16